We are live on ! Find out more
IBB icon

iShares Biotechnology ETF
IBB

520 hedge funds and large institutions have $5.06B invested in iShares Biotechnology ETF in 2017 Q1 according to their latest regulatory filings, with 76 funds opening new positions, 179 increasing their positions, 186 reducing their positions, and 76 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $4.15B → $5.06B (+$910M)

16.59% more ownership

Funds ownership: 161.41% → 177.99% (+17%)

0% more first-time investments, than exits

New positions opened: 76 | Existing positions closed: 76

0% less funds holding

Funds holding: 522 → 520 (-2)

4% less repeat investments, than reductions

Existing positions increased: 179 | Existing positions reduced: 186

5% less funds holding in top 10

Funds holding in top 10: 21 → 20 (-1)

35% less call options, than puts

Call options by funds: $496M | Put options by funds: $763M

Holders
520
Holders Change
-2
Holders Change %
-0.38%
% of All Funds
12.94%
Holding in Top 10
20
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-4.76%
% of All Funds
0.5%
New
76
Increased
179
Reduced
186
Closed
76
Calls
$496M
Puts
$763M
Net Calls
-$267M
Net Calls Change
+$81.9M

Top Buyers

Rank Fund Capital Flow
1
Goldman Sachs
Goldman Sachs
New York
+$187M
2
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$157M
3
Morgan Stanley
Morgan Stanley
New York
+$71.5M
4
JP Morgan Chase
JP Morgan Chase
New York
+$70.5M
5
CS
Credit Suisse
Switzerland
+$67.8M

Top Sellers

Rank Fund Capital Flow
1
N
Natixis
France
-$39.9M
2
RIG
RiverFront Investment Group
Virginia
-$35.6M
3
MIFH
Migdal Insurance & Financial Holdings
Israel
-$30.9M
4
PHS
PFM Health Sciences
California
-$30.1M
5
Jane Street
Jane Street
New York
-$29.9M
Name Holding Trade Value Shares
Change 		Change in
Stake
MIAN
151
Mariner Independent Advisor Network
Kansas
$3M -$1.59M -16,653 -35%
N
152
Nuveen
North Carolina
$2.93M +$2.87M +30,000 New
JWBC
153
J.W. Burns & Co
New York
$2.81M +$8.62K +90 +0.3%
JCM
154
Jacobi Capital Management
Pennsylvania
$2.76M +$1.15M +12,000 +71%
LPL Financial
155
LPL Financial
California
$2.73M +$508K +5,304 +23%
GI
156
Glovista Investments
New Jersey
$2.67M +$2.61M +27,285 New
IG
157
ING Group
Netherlands
$2.64M – – –
CTC
158
Central Trust Company
Missouri
$2.64M +$36.8K +384 +1%
DLCIG
159
D.L. Carlson Investment Group
New Hampshire
$2.6M +$25.8K +270 +1%
B
160
Barings
North Carolina
$2.57M +$2.23M +23,256 +775%
DCM
161
DAFNA Capital Management
California
$2.55M – – –
Cohen & Steers
162
Cohen & Steers
New York
$2.54M +$1.74M +18,186 +232%
SSB
163
Sandy Spring Bank
Maryland
$2.49M -$90.5K -945 -4%
1SB
164
1ST Source Bank
Indiana
$2.41M -$110K -1,149 -4%
US Bancorp
165
US Bancorp
Minnesota
$2.4M -$288K -3,009 -11%
IP
166
Intellectus Partners
California
$2.4M +$55.7K +582 +2%
HSBC Holdings
167
HSBC Holdings
United Kingdom
$2.3M -$3.44M -35,952 -60%
11A
168
10-15 Associates
New York
$2.29M +$286K +2,988 +15%
LCM
169
Lucas Capital Management
New Jersey
$2.25M -$517K -5,400 -19%
SRSA
170
S.R. Schill & Associates
Washington
$2.22M -$6.89K -72 -0.3%
SB
171
Simmons Bank
Arkansas
$2.21M +$2.17M +22,632 New
Squarepoint
172
Squarepoint
New York
$2.18M -$1.32M -13,836 -38%
FLAM
173
First Light Asset Management
Minnesota
$2.08M -$230K -2,400 -10%
ACM
174
Avalon Capital Management
California
$2.06M +$2.01M +21,021 New
State of Tennessee, Department of Treasury
175
State of Tennessee, Department of Treasury
Tennessee
$2.05M +$2.01M +21,000 New
5 6
7
8 9

IBB Hedge Fund Activity: Q1 2017 in Review

520 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in iShares Biotechnology ETF (IBB) for Q1 2017, worth a combined $5.06B — up 22% from $4.15B a quarter earlier.

Fund positioning in IBB was balanced in Q1 2017: 76 funds opened new positions, 76 closed out, 179 added to existing stakes and 186 trimmed.

The largest buyer was Goldman Sachs, adding an estimated $187M. The largest seller was Natixis, exiting entirely with an estimated $39.9M sold.

  • 520 institutional investors held iShares Biotechnology ETF (IBB) as of Q1 2017, down from 522 in Q4 2016.
  • Funds reported $5.06B of iShares Biotechnology ETF stock for Q1 2017, up 22% quarter-over-quarter.
  • 76 funds opened new iShares Biotechnology ETF positions in Q1 2017 and 76 closed out, a net change of 0 holders.
  • The largest iShares Biotechnology ETF buyer in Q1 2017 was Goldman Sachs, an estimated $187M added.
  • The largest iShares Biotechnology ETF seller in Q1 2017 was Natixis, an estimated $39.9M sold.

Based on aggregated 13F filings for Q1 2017.